On June 10, 2025, Rein Therapeutics, Inc. paused enrollment and dosing in its Phase 2 RENEW trial of LTI-03 due to a clinical hold by the FDA, while continuing in Australia, the UK, and Europe. So far, no serious drug-related adverse events have been reported during the trials.